Rovi schedules November 5 results for Rovi stock

Published on 10/15/2026 at 10:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Rovi stock trades at EUR 59.55 on October 15, 2026 at Lang & Schwarz. First-half revenue rose 13.00 percent to EUR 357.0 million.

Rovi results and operating drivers

Rovi will publish first nine months 2026 results on November 5, 2026.
First-half 2026 revenue increased 13.00 percent to EUR 357.0 million.
Rovi stock trades at EUR 59.55 at 10:02 a.m. CEST at Lang & Schwarz on October 15, 2026.

Rovi, ES0157261019, Illustration mit AI erstellt.

Rovi (ISIN ES0157261019) will publish its first nine months 2026 financial results on November 5, 2026, according to Rovi. The stock was trading at EUR 59.55 at Lang & Schwarz on October 15, 2026, at 10:02 a.m. CEST.

First-half growth sets the baseline

Yahoo Finance reported that Rovi's total revenue increased 13.00 percent to EUR 357.0 million in the first half of 2026. Operating revenue rose 9.00 percent to EUR 344.2 million, while gross profit increased 21.00 percent to EUR 237.1 million.

The figures include a EUR 62.4 million bargain purchase gain linked to the Phoenix manufacturing facility acquisition completed on April 1, 2026. Excluding that item, adjusted EBITDA fell 10.00 percent to EUR 58.8 million in the first half of 2026, making the quality of earnings a key investor issue.

What does the CDMO growth mean?

Rovi's contract development and manufacturing organization business grew 38.00 percent to EUR 106.3 million in the first half of 2026, according to Yahoo Finance. The specialty pharmaceutical division generated EUR 237.8 million, while Okedi sales rose 27.00 percent to EUR 34.0 million.

The counterweight was heparin, where sales declined 4.00 percent to EUR 130.1 million in the first half of 2026. Rovi maintained its 2026 outlook for operating revenue growth in the low to mid-single-digit percentage range, with the company also expecting the Phoenix facility to become operational between the end of 2027 and early 2028.

Three milestones frame the story

On April 1, 2026, Rovi completed the Phoenix facility acquisition, generating the EUR 62.4 million bargain purchase gain. On July 23, 2026, the company reported first-half revenue of EUR 357.0 million and adjusted EBITDA of EUR 58.8 million through Yahoo Finance. On October 15, 2026, the stock was trading at EUR 59.55 at Lang & Schwarz.

Next date for investors

The next substantiated company date is November 5, 2026, when Rovi is scheduled to release its first nine months 2026 financial results. The report will test whether CDMO expansion and Okedi growth can offset pressure in heparin and the ending Neparvis contract.

Stock quote and company profile

Rovi's euro quote was EUR 59.55 at Lang & Schwarz on October 15, 2026, at 10:02 a.m. CEST. The Madrid-listed pharmaceutical company enters the November reporting date with first-half operating revenue of EUR 344.2 million and a 2026 revenue-growth outlook in the low to mid-single-digit percentage range. The further course of trading is shown by the continuously updated real-time quote of Rovi stock.